Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4

Genes and Development

Volumn 29, Issue 5, 2015, Pages 489-494

  Guillemette, Shawna ^a   Serra, Ryan W ^a   Peng, Min ^a   Hayes, Janelle A ^a   Konstantinopoulos, Panagiotis A ^b   Green, Michael R ^a,a   Cantor, Sharon B ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BRCA2; CHD4; DNA repair; Hereditary cancer

Indexed keywords

BRCA2 PROTEIN; CHD4 PROTEIN; CISPLATIN; PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AUTOANTIGEN; CHD4 PROTEIN, HUMAN; HISTONE DEACETYLASE;

ARTICLE; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL LOSS; CELL MUTANT; CHROMOSOME ABERRATION; CLONE; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOSOME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERTANT; DRUG RESISTANCE; GENETICS; MUTATION; OVARIAN NEOPLASMS; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

AUTOANTIGENS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BRCA2; HUMANS; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; MUTATION; OVARIAN NEOPLASMS;

EID: 84924744200     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.256214.114     Document Type: Article

References (30)

1. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, et al. 2010. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17: 688–695.
2. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al. 2010. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141: 243–254.
3. The Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615.
4. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401–404.
5. Chiu RK, Brun J, Ramaekers C, Theys J, Weng L, Lambin P, Gray DA, Wouters BG. 2006. Lysine 63-polyubiquitination guards against translesion synthesis-induced mutations. PLoS Genet 2: e116.
6. Denslow SA, Wade PA. 2007. The human Mi-2/NuRD complex and gene regulation. Oncogene 26: 5433–5438.
7. Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. 2010. Suppression of Rev3, the catalytic subunit of Polz, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci 107: 20786–20791.
8. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. 2008. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451: 1111–1115.
9. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1.
10. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR. 2007. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449: 1073–1077.
11. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, et al. 2002. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297: 606–609.
12. Kim H, Dejsuphong D, Adelmant G, Ceccaldi R, Yang K, Marto JA, D’Andrea AD. 2014. Transcriptional repressor ZBTB1 promotes chromatin remodeling and translesion DNA synthesis. Mol Cell 54: 107–118.
13. Larsen DH, Poinsignon C, Gudjonsson T, Dinant C, Payne MR, Hari FJ, Rendtlew Danielsen JM, Menard P, Sand JC, Stucki M, et al. 2010. The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage. J Cell Biol 190: 731–740.
14. Le Gallo M, O’Hara AJ, Rudd ML, Urick ME, Hansen NF, O’Neil NJ, Price JC, Zhang S, England BM, Godwin AK, et al. 2012. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 44: 1310–1315.
15. Lehmann AR, Niimi A, Ogi T, Brown S, Sabbioneda S, Wing JF, Kannouche PL, Green CM. 2007. Translesion synthesis: Y-family polymerases and the polymerase switch. DNA Repair (Amst) 6: 891–899.
16. Lord CJ, Tutt AN, Ashworth A. 2015. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med 66: 455–470.
17. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM. 2011. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 29: 3008–3015.
18. O’Shaughnessy A, Hendrich B. 2013. CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now. Biochem Soc Trans 41: 777–782.
19. Pan M-R, Hsieh H-J, Dai H, Hung W-C, Li K, Peng G, Lin S-Y. 2012. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment. J Biol Chem 287: 6764–6772.
20. Pierce AJ, Johnson RD, Thompson LH, Jasin M. 1999. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13: 2633–2638.
21. Ramirez J, Hagman J. 2009. The Mi-2/NuRD complex: a critical epigenetic regulator of hematopoietic development, differentiation and cancer. Epigenetics 4: 532–536.
22. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, et al. 2008. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451: 1116–1120.
23. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E, Taniguchi T. 2009. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69: 6381–6386.
24. Siaud N, Barbera MA, Egashira A, Lam I, Christ N, Schlacher K, Xia B, Jasin M. 2011. Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains. PLoS Genet 7: e1002409.
25. Sims JK, Wade PA. 2011. Mi-2/NuRD complex function is required for normal S phase progression and assembly of pericentric heterochromatin. Mol Biol Cell 22: 3094–3102.
26. Smeenk G, Wiegant WW, Vrolijk H, Solari AP, Pastink A, van Attikum H. 2010. The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage. J Cell Biol 190: 741–749.
27. Stanley FKT, Moore S, Goodarzi AA. 2013. CHD chromatin remodelling enzymes and the DNA damage response. Mutat Res 750: 31–44.
28. Wang H, Zhang S-Y, Wang S, Lu J, Wu W, Weng L, Chen D, Zhang Y, Lu Z, Yang J, et al. 2009. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. Neuro-oncol 11: 790–802.
29. Xie K, Doles J, Hemann MT, Walker GC. 2010. Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci 107: 20792–20797.
30. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, et al. 2013. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci 110: 2916–2921.